Table 3 Association [OR (95% CI)] between creatinine-corrected DEHP metabolites and cancer; NHANES 2011–2018

∑DEHP

6147

6147

6147

  Q1: < 5.1 ng/mg crt

Reference

Reference

Reference

  Q2: 5.1–5.6 ng/mg crt

1.39 (1.29, 1.50)

1.20 (1.10, 1.30)

1.17 (1.08, 1.27)

  Q3: 5.7–6.1 ng/mg crt

1.65 (1.53, 1.78)

1.26 (1.16, 1.37)

1.22 (1.13, 1.33)

  Q4: > 6.1 ng/mg crt

1.56 (1.45, 1.69)

1.32 (1.22, 1.44)

1.29 (1.19, 1.40)

p trend

 < 0.001

 < 0.001

 < 0.001

MEHHP

6147

6147

6147

  Q1: < 3.6 ng/mg crt

Reference

Reference

Reference

  Q2: 3.6–4.1 ng/mg crt

1.78 (1.65, 1.93)

1.61 (1.49, 1.75)

1.58 (1.45, 1.72)

  Q3: 4.2–4.6 ng/mg crt

1.63 (1.51, 1.77)

1.41 (1.29, 1.53)

1.37 (1.25, 1.49)

  Q4: > 4.6 ng/mg crt

1.74 (1.61, 1.88)

1.54 (1.41, 1.67)

1.53 (1.41, 1.67)

p trend

 < 0.001

 < 0.001

 < 0.001

MEHP

6147

6147

6147

  Q1: < 1.9 ng/mg crt

Reference

Reference

Reference

  Q2: 2.0–2.5 ng/mg crt

1.10 (1.03, 1.19)

1.15 (1.07, 1.24)

1.15 (1.06, 1.24)

  Q3: 2.6–3.2 ng/mg crt

1.03 (0.96, 1.10)

1.24 (1.15, 1.34)

1.25 (1.16, 1.35)

  Q4: > 3.2 ng/mg crt

0.84 (0.78, 0.90)

1.16 (1.07, 1.26)

1.14 (1.05, 1.24)

p trend

 < 0.001

 < 0.001

 < 0.001

MEOHP

6147

6147

6147

  Q1: < 3.1 ng/mg crt

Reference

Reference

Reference

  Q2: 3.1–3.6 ng/mg crt

1.48 (1.37, 1.60)

1.28 (1.18, 1.39)

1.27 (1.16, 1.38)

  Q3: 3.7–4.2 ng/mg crt

1.62 (1.50, 1.75)

1.23 (1.14, 1.34)

1.21 (1.11, 1.32)

  Q4: > 4.2 ng/mg crt

1.70 (1.58, 1.84)

1.40 (1.28, 1.52)

1.37 (1.26, 1.49)

p trend

 < 0.001

 < 0.001

 < 0.001

MECCP

6147

6147

6147

  Q1: < 4.1 ng/mg crt

Reference

Reference

Reference

  Q2: 4.1–4.5 ng/mg crt

1.30 (1.20, 1.40)

1.06 (0.97, 1.15)

1.03 (0.95, 1.12)

  Q3: 4.6–5.0 ng/mg crt

1.49 (1.38, 1.61)

1.09 (1.00, 1.18)

1.06 (0.97, 1.15)

  Q4: > 5.0 ng/mg crt

1.58 (1.46, 1.70)

1.23 (1.14, 1.34)

1.22 (1.12, 1.32)

p trend

 < 0.001

 < 0.001

 < 0.001